Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) COO Jennifer Jarrett sold 11,551 shares of the company's stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $17.55, for a total value of $202,720.05. Following the completion of the transaction, the chief operating officer now owns 215,253 shares of the company's stock, valued at approximately $3,777,690.15. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Jennifer Jarrett also recently made the following trade(s):
- On Monday, March 18th, Jennifer Jarrett sold 13,449 shares of Arcus Biosciences stock. The shares were sold at an average price of $17.92, for a total value of $241,006.08.
- On Monday, February 26th, Jennifer Jarrett sold 24,555 shares of Arcus Biosciences stock. The shares were sold at an average price of $20.07, for a total value of $492,818.85.
Arcus Biosciences Price Performance
Shares of NYSE RCUS opened at $18.88 on Friday. The stock has a 50 day moving average price of $17.17 and a 200 day moving average price of $16.96. Arcus Biosciences, Inc. has a 52 week low of $12.95 and a 52 week high of $25.47.
Elon’s New A.I. Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its earnings results on Wednesday, February 21st. The company reported ($1.08) earnings per share for the quarter, beating analysts' consensus estimates of ($1.09) by $0.01. Arcus Biosciences had a negative return on equity of 57.17% and a negative net margin of 262.39%. The firm had revenue of $31.00 million for the quarter, compared to the consensus estimate of $28.30 million. During the same quarter last year, the business posted ($0.93) EPS. The company's revenue was down 8.8% compared to the same quarter last year. As a group, sell-side analysts predict that Arcus Biosciences, Inc. will post -3.59 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in Arcus Biosciences by 8.0% during the 1st quarter. BlackRock Inc. now owns 10,139,020 shares of the company's stock worth $184,936,000 after buying an additional 749,972 shares during the period. State Street Corp lifted its holdings in Arcus Biosciences by 55.1% during the 1st quarter. State Street Corp now owns 5,496,253 shares of the company's stock worth $100,251,000 after buying an additional 1,951,970 shares during the period. FMR LLC lifted its holdings in Arcus Biosciences by 4.9% during the 3rd quarter. FMR LLC now owns 4,780,052 shares of the company's stock worth $85,802,000 after buying an additional 222,280 shares during the period. Vanguard Group Inc. lifted its holdings in Arcus Biosciences by 4.2% during the 4th quarter. Vanguard Group Inc. now owns 4,680,716 shares of the company's stock worth $89,402,000 after buying an additional 186,898 shares during the period. Finally, Boxer Capital LLC raised its position in shares of Arcus Biosciences by 11.9% in the 2nd quarter. Boxer Capital LLC now owns 1,602,200 shares of the company's stock worth $32,541,000 after acquiring an additional 170,000 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
RCUS has been the topic of a number of recent analyst reports. Mizuho cut their target price on Arcus Biosciences from $51.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday, January 30th. Wedbush reaffirmed an "outperform" rating and issued a $30.00 target price on shares of Arcus Biosciences in a research report on Thursday, February 22nd. Finally, Truist Financial reissued a "buy" rating and set a $50.00 price target on shares of Arcus Biosciences in a research report on Monday, March 25th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $41.25.
Get Our Latest Analysis on Arcus Biosciences
Arcus Biosciences Company Profile
(
Get Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
